Sign up to save your podcasts
Or
Share From drop to double: Akero’s surging stock
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
From drop to double: Akero’s surging stock
When Akero’s stock dropped after a trial setback, why did RTW double down that same day? CEO Andrew Cheng joins RTW’s Rod Wong to share how he navigated the biotech storm, why he believed in efruxifermin (EFX,) and what’s next for liver disease treatment.
PODCAST TEAM
Producer: Devon Leaver
Editor: Dominique Guerra
Production Coordinator: YingYu Lin
Featuring: Andrew Cheng, CEO of Akero Therapeutics, moderated by Roderick Wong, MD, Managing Partner and Chief Investment Officer RTW Investments.
FOLLOW US
Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.
To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.
CHAPTERS
00:00 – Rod Wong in 2023
00:22 – Introduction
01:01 – Introducing Akero Therapeutics and MASH
03:51 – Discussing Akero’s Trials and Setbacks
08:32 – Becoming pioneers in pre-cirrhotic and cirrhotic treatment
11:05 – Challenges of being a biotech CEO
12:52 – Outro and Disclaimer
DISCLAIMER
This interview was given by Andrew Cheng, CEO of Akero Therapeutics, and moderated by Roderick Wong, MD, Managing Partner and Chief Investment Officer RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.
View all episodes
By RTW Investments, LPWhen Akero’s stock dropped after a trial setback, why did RTW double down that same day? CEO Andrew Cheng joins RTW’s Rod Wong to share how he navigated the biotech storm, why he believed in efruxifermin (EFX,) and what’s next for liver disease treatment.
PODCAST TEAM
Producer: Devon Leaver
Editor: Dominique Guerra
Production Coordinator: YingYu Lin
Featuring: Andrew Cheng, CEO of Akero Therapeutics, moderated by Roderick Wong, MD, Managing Partner and Chief Investment Officer RTW Investments.
FOLLOW US
Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.
To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.
CHAPTERS
00:00 – Rod Wong in 2023
00:22 – Introduction
01:01 – Introducing Akero Therapeutics and MASH
03:51 – Discussing Akero’s Trials and Setbacks
08:32 – Becoming pioneers in pre-cirrhotic and cirrhotic treatment
11:05 – Challenges of being a biotech CEO
12:52 – Outro and Disclaimer
DISCLAIMER
This interview was given by Andrew Cheng, CEO of Akero Therapeutics, and moderated by Roderick Wong, MD, Managing Partner and Chief Investment Officer RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.